More than 90% of private equity fund managers are predicting a rise in the volume of distressed dealmaking over the next 12 months amid the fallout from the coronavirus crisis - but it may not
Asian private equity investor CDIB Capital has brought former CVC Capital Asian operations director Stephen Li to boost its Chinese investment abilities.
Vitruvian Partners has bought European digital signature and identity solutions business Scrive.
A new coronavirus economic recovery fund targeting South Africa has been launched by Ninety One, which has just demerged from Investec Bank, and Ethos Private Equity.
The private equity arm of activist investor Elliott Management Corp has teamed with Siris Capital to help existing portfolio business Travelport Worldwide weather the coronavirus crisis with up to $1bn of new financing.
Sycamore Partners is reportedly in talks to buy US department store chain JC Penney out of bankruptcy, just a month after backing out of an agreed buyout of troubled fellow retailer Victoria's Secret.
Mainland-based firms OcuMension Therapeutics and Immunotech Biopharm sealed their Hong Kong IPOs at the top of guidance, riding on support from both institutional and retail investors.
Cathay Media and Education Group is set to wrap up bookbuilding for its Hong Kong IPO two days early, on the back of strong demand from institutional investors, according to a source close to the
In this round-up, regulators release official guidelines for follow-on offerings in the Nasdaq-style Star market, issuers of onshore ‘enterprise bonds’ get an extension on their regulatory approvals, and a financial unit of JD.com starts pre-listing
In April, 80% of the money raised by US IPOs was for companies whose purpose is to fund acquisitions
The Shanghai Stock Exchange stunned the market on Tuesday by halting Ant Group’s $34bn IPO, set to be the largest listing in history, just two days before the company’s planned stock market debut. The extraordinary
Chinese property manager Jinke Smart Services Group has launched its IPO. It is aiming to pocket up to HK$6.3bn ($815.9m) from the deal.
China’s decision to clamp down on Ant Group has derailed an IPO of at least $34bn, despite execution being finished last week. The move appears to be little more than political muscle-flexing by Beijing. The
Blue Moon Group, a Chinese detergent maker, saw the book for its up to HK$9.8bn ($1.3bn) IPO covered within hours of opening on Friday.
Gland Pharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, has set the final terms for its Rp64.8bn ($866.5m) IPO in India.
Chinese biopharmaceutical firm RemeGen has raised HK$3.99bn ($514.7m) after pricing its IPO at the top of the marketed range, according to a source familiar with the matter.
The Shanghai bourse stunned the market on Tuesday after halting Ant Group’s $34bn IPO, a deal which was set to be the largest listing in history. The extraordinary move, likely spurred by comments from Ant’s
South Korean game developer Kakao Games is set to list in September for up to W340bn ($284.8m), reviving the deal two years after dropping its initial IPO plans.
Thai express delivery company Kerry Express launched its IPO this week, aiming to raise up to Bt8.4bn ($278.2m) in proceeds.
The volatility has caused some M&A and initial public offering deals to be put on hold
